{"id":"W4306743619","doi":"10.1111/bjh.18519","title":"<scp>Real‐world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp>‐2 retrospective chart review study","year":2022,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"MD Precision (Canada); Precision Nanosystems (Canada)","funders":"National Cancer Institute; Allergan; Incyte; Genentech; Sunesis; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Gilead Sciences; Sanofi; Amgen; Pfizer; MorphoSys; Celgene; BeiGene; Patient-Centered Outcomes Research Institute","keywords":"Mantle cell lymphoma; Medicine; Bruton's tyrosine kinase; Refractory (planetary science); Chart; Cancer research; Ibrutinib; Tyrosine kinase; Internal medicine; Lymphoma; Oncology; Leukemia; Biology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007928484,0.0003823221,0.001316709,0.0002845729,0.0003718161,0.00008463518,0.0003798158,0.00008278531,0.0001213403],"category_scores_gemma":[0.0008307354,0.0002968596,0.0001965915,0.001019676,0.0002208438,0.0004058886,0.0002750156,0.00082995,0.00002123408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007243969,"about_ca_system_score_gemma":0.000377515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003162796,"about_ca_topic_score_gemma":0.0006014985,"domain_scores_codex":[0.9958832,0.0008499392,0.001110535,0.0005606734,0.001006544,0.0005890867],"domain_scores_gemma":[0.9972907,0.0004034825,0.0009622689,0.0004732047,0.0005940057,0.0002763773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00008047604,0.006952579,0.9021914,0.0001889914,0.0001448341,0.06868185,0.00210541,0.000001852477,0.00001662489,0.000008803067,0.01884406,0.0007831439],"study_design_scores_gemma":[0.01118433,0.002671718,0.9438116,0.002025467,0.000361625,0.01308276,0.002398943,0.000001642714,0.000254652,0.000006281215,0.02412059,0.00008039992],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737216,0.0234897,8.786405e-7,0.0002120471,0.0004581191,0.001424032,0.00005352334,0.00002533863,0.0006147543],"genre_scores_gemma":[0.9939524,0.003882888,0.00007101538,0.0008316036,0.0001109831,0.0004074262,0.000027527,0.00007336701,0.0006427711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05559909,"threshold_uncertainty_score":0.9999484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006174186714432873,"score_gpt":0.2268818697572513,"score_spread":0.2207076830428185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}